NCT06393361View on ClinicalTrials.gov

Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Interventions
DRUG

Chidamide; Decitabine; Anti-PD-1 Antibody

Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

DRUG

Brentuximab Vedotin, anti-PD-1 antibody.

Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

Trial Locations (1)

100853

RECRUITING

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER